Cardiovascular
Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide. At Boehringer Ingelheim we address unmet medical need by providing innovative treatments that improve the care of patients suffering from a range of cardiovascular conditions including irregular heart beats (atrial fibrillation), stroke, blood clots in deep veins or lungs (deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack (myocardial infarction).
Acute ischaemic stroke, the most common type of stroke, occurs when the blood supply to part of the brain is blocked by either a blood clot in a brain vessel or atherosclerosis (fatty deposits or plaques lining vessel walls). A stroke can lead to disability or even death and always requires quick, acute treatment. Boehringer Ingelheim led the way in stroke care by developing the only licensed blood clot dissolving treatment (thrombolytic) for acute ischaemic stroke therapy, which is now used in stroke centres worldwide.
Boehringer Ingelheim also sponsors the angels initiative: a programme that helps doctors to set up and optimise acute stroke networks with the support of local and international stroke societies.
-
-
DOWNLOAD PDF (116.95 KB)
Recognising the symptoms of a stroke
-
Vision & Values
Anna Higgs had a severe stroke at the age of 24. For years she has been struggling with the physical and psychological consequences.
-
Angels Initiative
Acute Ischaemic Stroke
We are working together with our partners such as the ESO and various local societies, academics and industry partners towards a common goal, to improve care for as many people as possible who have suffered a stroke.